Bristol-Myers Squibb Company Ce

CELG-RI · NYSE
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$2,195$1,313$2,456$76
Dep. & Amort.$1,011$1,011$1,012$1,880
Deferred Tax-$359-$437$223-$791
Stock-Based Comp.$139$137$144$120
Change in WC$3,055$15-$1,871$1,276
Other Non-Cash$270$1,878-$10$1,878
Operating Cash Flow$6,311$3,917$1,954$4,439
Investing Activities
PP&E Inv.-$320-$361-$260-$378
Net Acquisitions-$2,387-$285-$78$286
Inv. Purchases-$665-$621-$636-$371
Inv. Sales/Matur.$878$524$232$267
Other Inv. Act.$792$270$243$0
Investing Cash Flow-$1,702-$473-$499-$196
Financing Activities
Debt Repay.-$224-$585$368-$405
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid-$1,263-$1,262-$1,258-$1,218
Other Fin. Act.-$3$11-$103-$19
Financing Cash Flow-$1,490-$1,836-$993-$1,642
Forex Effect-$4$128$66-$147
Net Chg. in Cash$3,115$1,736$528$2,454
Supplemental Information
Beg. Cash$12,611$10,875$10,347$7,893
End Cash$15,726$12,611$10,875$10,347
Free Cash Flow$5,991$3,556$1,694$4,061
Bristol-Myers Squibb Company Ce (CELG-RI) Financial Statements & Key Stats | AlphaPilot